Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Li, Chuan Jiang ^a   Li, Liang ^a   Lin, Li ^a   Jiang, Hai Xia ^a   Zhong, Ze Yan ^a   Li, Wei Mo ^a   Zhang, Yan Jun ^b   Zheng, Ping ^a   Tan, Xu Hui ^a   Zhou, Lin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 REDUCTASE; INTERLEUKIN 10; TACROLIMUS;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHINESE; COMT GENE; CONTROLLED STUDY; CYP3A4 GENE; CYP3A5 GENE; DRUG BLOOD LEVEL; FEMALE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HUMAN; IL 10 GENE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POR GENE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; KIDNEY TRANSPLANTATION; MALE; NADPH-FERRIHEMOPROTEIN REDUCTASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 84907033516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086206     Document Type: Article

References (30)

1. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, et al. (2007) Reduced exposure to calcineurin inhibitors in renal transplantation.N Engl J Med 357: 2562-2575. (Pubitemid 350294223)
2. Kuypers DRJ, Claes K, Evenepoel P, Maes B, Vanrenterghem Y (2004) Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 75: 434-447. (Pubitemid 38534564)
3. Masuda S, Inui K (2006) An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 112: 184.
4. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, et al. (2009) Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 31: 139-152.
5. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR (2012) In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther 92: 366-375.
6. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5: 243-272. (Pubitemid 38499965)
7. Roy JN, Barama A, Poirier C, Vinet B, Roger M (2006) CYP3A4, CYP3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 16: 659-665. (Pubitemid 44223077)
8. Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De Meyer M, et al. (2006) CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 6: 2706-2713. (Pubitemid 44571691)
9. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, et al. (2004) CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14: 471-478. (Pubitemid 38971237)
10. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, et al. (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3: 477-483. (Pubitemid 36560101)
11. Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, et al. (2004) Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 44: 135-140. (Pubitemid 38114311)
12. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, et al. (2004) The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 4: 914-919. (Pubitemid 38745590)
13. Dai Z, Papp AC, Wang D, Hampel H, Sadee W (2008) Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics 1: 24.
14. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W (2011) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 11: 274-286.
15. He BX, Shi L, Qiu J, Tao L, Li R, et al. (2011) A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. Basic Clin Pharmacol Toxicol 108: 208-213.
16. Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat MR, et al. (2007) Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 8: 443-453. (Pubitemid 46746352)
17. Zhang X, Li L, Ding X, Kaminsky LS (2011) Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab Dispos 39: 1433-1439.
18. de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR (2011) The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 12: 1281-1291.
19. Jacobson PA, Oetting WS, Brearley AM, Leduc R, Guan W, et al. (2011) Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 91: 300-308.
20. Zhang X, Wang Z, Fan J, Liu G, Peng Z (2011) Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. Eur J Clin Pharmacol 67: 803-813.
21. Li L, Li CJ, Zheng L, Zhang YJ, Jiang HX, et al. (2011) Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study. Eur J Clin Pharmacol 67: 787-795.
22. Li L, Li CJ, Zhang YJ, Zheng L, Jiang HX, et al. (2011) Simultaneous detection of CYP3A5 and MDR1 polymorphisms based on the SNaPshot assay. Clin Biochem 44: 418-422.
23. Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, et al. (2008) CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 30: 689-699.
24. Miura M, Satoh S, Kagaya H, Saito M, Numakura K, et al. (2011) Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics 12: 977-984.
25. Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, et al. (2013) Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics 23: 251-261.
26. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, et al. (2011) A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 57: 1574-1583.
27. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, et al. (2012) The new CYP3A4 intron 6 C.T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics 22: 373-380.
28. Elens L, Hesselink DA, van Schaik RH, van Gelder T (2013) The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br J Clin Pharmacol 75: 1545-1547.
29. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, et al. (2010) Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87: 721-726.
30. Chen SY, Li JL, Meng FH, Wang XD, Liu T, et al. (2013) Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism - a prospective, randomized, controlled study. Clin Transplant 27: E272-E281.